More recently, CBD was investigated in a randomized double-blind parallel-group trial, on patients with schizophrenia receiving CBD (1000 mg/day; N = 43) or placebo (N = 45) alongside their existing antipsychotic medication for 6 weeks. This evidence concerns the gene OPN1MW and schizophrenia.